GlassScriptPhysician profile
Martin G Hoffman
NPI 1922035617
$316,550.66
in general payments reported to CMS, 2019-2025
35 companies · $108K in 2025
The $108K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $9,364 · 2021: $25K · 2022: $26K · 2023: $53K · 2024: $52K · 2025: $108K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Consulting Fee: $90K · Food and Beverage: $8,955 · Travel and Lodging: $6,350 · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,152.50 |
| Consulting Fee | $90,267.50 |
| Food and Beverage | $8,954.99 |
| Travel and Lodging | $6,349.59 |
| Education | $181.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $136,436.38 | 2019-2025 | Epclusa, Livdelzi, Vemlidy |
| Capsovision, INC. | $89,300.00 | 2023-2025 | Capsocam Plus, Capsocam Colon |
| Abbvie INC. | $43,715.68 | 2019-2025 | |
| Madrigal Pharmaceuticals | $41,417.84 | 2024-2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $1,160.01 | 2019-2024 | Ocaliva |
| Celgene Corporation | $816.34 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $641.27 | 2019-2025 | Stelara, Tremfya, Simponi |
| Mallinckrodt Hospital Products INC. | $487.64 | 2021-2025 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $481.91 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $279.16 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.75 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $214.81 | 2020-2025 | Iqirvo, Bylvay |
| Regeneron Healthcare Solutions, INC. | $167.93 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $115.12 | 2022-2025 | Rebyota |
| Bayer Healthcare Pharmaceuticals INC. | $94.15 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $92.91 | 2023-2024 | Omvoh |
| Eisai INC. | $91.54 | 2019 | |
| Ardelyx, INC. | $77.74 | 2023-2024 | Ibsrela |
| Genzyme Corporation | $73.46 | 2019-2023 | |
| Celltrion USA INC. | $69.86 | 2024 | Zymfentra |
| E.R. Squibb & Sons, L.L.C. | $68.91 | 2022 | |
| Medtronic, INC. | $58.49 | 2021 | |
| Fujifilm Healthcare Americas Corporation | $56.78 | 2024-2025 | Utaswako Afp-L3 |
| Mirum Pharmaceuticals, INC. | $55.89 | 2024 | Livmarli |
| Shionogi INC | $52.70 | 2019-2020 | |
| Redhill Biopharma INC. | $49.57 | 2021-2023 | Talicia |
| Astrazeneca Pharmaceuticals LP | $45.78 | 2023 | Imfinzi |
| Orphalan INC | $44.33 | 2024 | Cuvrior |
| Merck Sharp & Dohme LLC | $26.38 | 2019 | |
| Ironwood Pharmaceuticals, INC | $24.62 | 2023 | Linzess |
| Ultragenyx Pharmaceutical INC. | $22.31 | 2025 | Dojolvi |
| Exact Sciences Corporation | $21.53 | 2025 | The Cologuard Plus Collection Kit |
| Ucb, INC. | $18.78 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.62 | 2023 | Cyltezo |
| Boston Scientific Corporation | $8.47 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.